NANJING, China, Nov. 22, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR) ("Simcere" or the "Company"), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that the annual general meeting of shareholders (the "Meeting") will be held on Thursday, December 19, 2013 at 9 a.m.Beijing time. The meeting will be held at No.699-18, Xuanwu Avenue, Xuanwu District, Nanjing, People's Republic of China.
The meeting's main purposes are:
- To receive a report on the Company's operations.
- To transact any other business properly brought before the Meeting.
All shareholders of record at the close of business on November 18, 2013 will be entitled to attend and vote at the Meeting, and at any adjournment or postponement thereof, or to appoint a proxy to attend and vote in his/her place. The proxy need not be a shareholder of the Company.
This notice and other information with regards to the Meeting are available on the investor relations section of the Company's website: www.simcere.com.
On August 28, 2013, the Company announced that it has signed a definitive merger agreement with Simcere Holding Limited ("Parent") and Simcere Acquisition Limited ("Merger Sub"), pursuant to which Parent will acquire the Company (the "Transaction") for US$4.83 per ordinary share of the Company or US$9.66 per American depositary share, each representing two Shares. Matters relating to the Transaction are not being submitted for approval by the shareholders of the Company at the Meeting. On November 19, 2013, the Company announced that a separate extraordinary general meeting of the Company would be convened on Tuesday, December 19, 2013 at 10 a.m.Beijing time at No. 699-18, Xuan Wu Avenue, Xuan Wu District, Nanjing, Jiangsu Province 210042, People's Republic of China.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group ("Simcere") (NYSE: SCR) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. These forward-looking statements can be identified by terminology such as "if," "will," "expected," and similar statements. Forward-looking statements involve inherent risks, uncertainties and assumptions. Risks, uncertainties and assumptions include: uncertainties as to how the Company's shareholders will vote at the meeting of shareholders; the possibility that competing offers will be made; the possibility that debt financing may not be available; the possibility that various closing conditions for the transaction may not be satisfied or waived; and other risks and uncertainties discussed in documents filed with the SEC by the Company, as well as the Schedule 13E-3 transaction statement and the proxy statement to be filed by the Company. These forward-looking statements reflect the Company's expectations as of the date of this press release. You should not rely upon these forward-looking statements as predictions of future events. Simcere does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Investor and Media Contacts:
Simcere Pharmaceutical Group
Tel: 86-25-8556-6666 / Ext. 8857
In the United States:
Brunswick Group LLC
SOURCE Simcere Pharmaceutical Group